The objective of this study is to assess the safety, efficacy, and durability of up to two REACT® injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD:
- Cohort 1: Two scheduled REACT® injections given 3 months (+60 days) within 24-month follow-up
- Cohort 2: One scheduled REACT® injection with a possible second REACT® injection, no less than 3 months after the first one, within 30 days (+30 days) of meeting a renal function redose trigger (triggered up to 18 months following the first REACT® injection) within 24-month follow-up.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.